It has been reported that fluorouracil, paclitaxel, and oxaliplatin can increase the sensitivity of colorectal cancer cells to TRAIL by reducing the expression of antiapoptotic molecules, such as c-FLIP, BCL-XL, NF-κβ, or increasing TRAIL death receptors [19,21,40]. Here, BCL2L1 is linked to colorectal cancer.